Pharmacokinetic and pharmacodynamic study of S-1 and its effects in patients with the digestive organ cancer with reference to genetic polymorphism and activity of CYP2A6 [cytochrome P450 2A6 enzyme] and DPD [dihydropyrimidine dehydrogenase]

Trial Profile

Pharmacokinetic and pharmacodynamic study of S-1 and its effects in patients with the digestive organ cancer with reference to genetic polymorphism and activity of CYP2A6 [cytochrome P450 2A6 enzyme] and DPD [dihydropyrimidine dehydrogenase]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary)
  • Indications Gastrointestinal cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 23 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top